Inhibrx ROCE
Was ist das ROCE von Inhibrx?
ROCE von Inhibrx, Inc. ist 758.45%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx
Was macht Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Unternehmen mit roce ähnlich Inhibrx
- Molecular Data Inc hat ROCE von 682.69%
- 9 Meters Biopharma hat ROCE von 684.23%
- Biosig Technologies Inc hat ROCE von 689.29%
- BioCardia hat ROCE von 724.72%
- Elfato hat ROCE von 731.09%
- ContraFect Corp hat ROCE von 754.78%
- Inhibrx hat ROCE von 758.45%
- Corvus Gold hat ROCE von 760.11%
- Havn Life Sciences Inc hat ROCE von 763.04%
- Sabine Royalty Trust hat ROCE von 785.68%
- Winners hat ROCE von 793.33%
- American Environmental hat ROCE von 831.71%
- Killi hat ROCE von 837.33%